title: FKBPs in chromatin modification and cancer.
abstract: FK506-binding proteins (FKBPs) are intracellular receptors for FK506 and rapamycin, immunosuppressants that have recently been utilized as anticancer drugs. In the cytoplasm, FKBPs and these drugs modulate signal transduction pathways. However, recent reports reveal novel functions of FKBPs in the nucleus, which include regulation of transcription factors, histone chaperone activity, and modifications of chromatin structure. These activities are known to affect gene expression, DNA repair, and DNA replication. Therefore, elucidation of the nuclear functions of FKBPs will help researchers and clinicians better understand how immunosuppressants work as anticancer drugs, which might in turn lead to novel designs of cancer therapy.
authors.affiliation: Department of Biotechnology, Asia University, Taichung 41354, Taiwan.
authors.forename: Ya-Li
authors.initials: YL
authors.lastname: Yao
authors.forename: Ya-Chen
authors.initials: YC
authors.lastname: Liang
authors.forename: Huai-Huei
authors.initials: HH
authors.lastname: Huang
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Yang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002843:Chromatin / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009369:Neoplasms / Q000473:pathology*; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology; D022021:Tacrolimus Binding Proteins / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D002843:Chromatin; D007166:Immunosuppressive Agents; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus; D016559:Tacrolimus